Unlock instant, AI-driven research and patent intelligence for your innovation.

Twisted gastrulation polypeptides and uses thereof

a gastrulation polypeptide and polypeptide technology, applied in the direction of peptide/protein ingredients, peptide sources, extracellular fluid disorders, etc., can solve the problems of poor therapeutic response, many individuals are refractory to even high doses, and the effect of epo is not uniformly effectiv

Pending Publication Date: 2019-07-18
ACCELERON PHARMA INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present patent discloses a method for increasing red blood cell and / or hemoglobin levels, reducing blood transfusion-dependence, and preventing iron overload in a subject through the use of a TWSG-Fc fusion protein or polypeptide, multimeric polypeptide complex, polynucleotide, composition, vector, or host cell. The invention is based on the discovery that the TWSG-Fc fusion protein can inhibit BMP signaling and increase red blood cell and / or hemoglobin levels, reduce blood transfusion-dependence, and increase iron levels, thereby treating or preventing iron overload and dysregulation of BMP signaling. The use of the TWSG-Fc fusion protein or its related components in a medicament is also disclosed.

Problems solved by technology

EPO is not uniformly effective, and many individuals are refractory to even high doses (Horl et al., 2000, Nephrol Dial Transplant 15, 43-50).
Several factors, including inflammation, iron and vitamin deficiency, inadequate dialysis, aluminum toxicity, and hyperparathyroidism may predict a poor therapeutic response.
Recent evidence suggests that higher doses of EPO may be associated with an increased risk of cardiovascular morbidity, tumor growth, and mortality in some patient populations (Krapf et al., 2009, Clin J Am Soc Nephrol 4:470-480; Glaspy, 2009, Annu Rev Med 60:181-192).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Twisted gastrulation polypeptides and uses thereof
  • Twisted gastrulation polypeptides and uses thereof
  • Twisted gastrulation polypeptides and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

n of Human TWSG-Fc Fusion Protein

[0198]Applicants constructed a soluble TWSG fusion protein (TWSG-Fc) in which full-length human TWSG (FIG. 1, SEQ ID NO: 8) was attached at its C-terminus to a human IgG1 Fc domain (SEQ ID NO: 3) with a minimal linker. TWSG-Fc (FIG. 2, SEQ ID NO: 9) was initially expressed by transient transfection in COS cells, as were N-glycosylation variants of TWSG-Fc (see below). In brief, COS cells (ATCC®) were transfected overnight with plasmid encoding TWSG-Fc using FuGENE® 6 transfection reagent (Promega). The next day, cells were washed with phosphate-buffered saline, and serum-free medium was added. After incubation for 72 h, the COS-conditioned medium was harvested, filtered, and loaded on a MabSelect SuRe column (GE Healthcare, UK). Fusion protein was eluted with 0.1 M glycine (pH 3.0), and the eluted fractions were immediately neutralized by addition 1 M Tris (pH 8.0) in a 1:10 ratio. Protein was quantitated using a NanoDrop™ spectrophotometer (Thermo F...

example 2

nding to Murine TWSG and Human TWSG-Fc

[0203]Previous studies have determined that TWSG, or its nonmammalian homolog Tsg, binds with high affinity to BMP2, BMP4, and BMP7 (Oelgeschläger et al., 2000, Nature 405:757-763; Scott et al., 2001, Nature 410:475-478; Chang et al., 2001, Nature 410:483-487). Since these studies have not systematically evaluated TWSG (or Tsg) binding to other TGFβ superfamily ligands, Applicants used surface plasmon resonance to investigate and characterize such binding. In an initial qualitative screen, recombinant murine TWSG (mTWSG; R&D Systems, Minneapolis, Minn.) was covalently immobilized on a BIACORE™ CMS chip, and more than 30 ligands generated in-house or obtained from R&D Systems were injected individually over the captured mTWSG to characterize their degree of binding at room temperature. Based on the results of this screen, Applicants subjected selected ligands to quantitative characterization of binding to human TWSG fusion protein at physiologic ...

example 3

n of Ligand Signaling by TWSG-Fc in Cell-Based Assays

[0206]Reporter gene assays were used to determine the ability of human TWSG-Fc to inhibit signaling by BMP2, BMP4, BMP6, BMP7, BMP9, and BMP10. These assays are based on human glioblastoma (T98G) or hepatocellular carcinoma (HepG2) cell lines transfected with a pGL3 BRE (BMP response element) reporter plasmid (Korchynskyi et al., 2002, J Biol Chem 277: 4883-4891) as well as a Renilla reporter plasmid (pRLCMV) to control for transfection efficiency. BMP response elements from the Id1 promoter are present in the promoter of the pGL3 BRE reporter plasmid, so this vector is of general use for factors signaling through Smad1 and Smad5.

[0207]On the first day of the assay, T98G cells (ATCC®: CRL_1690™) or HepG2 cells (ATCC®: HB-8065™) were distributed in 48-well plates at 8.5×104 cells per well or 12.5×104 cells per well, respectively. On the second day, a solution containing 10 μg pGL3 BRE, 100 ng pRLCMV, 30 μl Fugene HD (Roche Applied ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Login to View More

Abstract

In certain aspects, the present invention provides compositions and methods for altering iron metabolism to increase red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

Description

RELATED APPLICATIONS[0001]This application claims the benefit of priority to U.S. Provisional Patent Application Ser. No. 62 / 395,088, filed Sep. 15, 2016, which is herein incorporated by reference in its entirety.SEQUENCE LISTING[0002]The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 8, 2017, is named APH-00125_SL.txt and is 27,134 bytes in size.BACKGROUND OF THE INVENTION[0003]The mature red blood cell (RBC), or erythrocyte, is responsible for oxygen transport in the circulatory systems of vertebrates. Red blood cells contain high concentrations of hemoglobin, a protein that binds oxygen in the lungs at relatively high partial pressure of oxygen (pO2) and delivers oxygen to areas of the body with a relatively low pO2.[0004]Mature red blood cells are produced from pluripotent hematopoietic stem cells in a process termed erythropoiesis. P...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/47A61P7/06
CPCC07K14/4703A61P7/06C07K2319/30A61K38/00C07K14/52C07K19/00A61K45/06
Inventor RAJASEKHAR SURAGANI, NAGA VENKATA SAIGRINBERG, ASYASAKO, DIANNE
Owner ACCELERON PHARMA INC